Yvette Drew: search on Z-Library

Fundraising September 15, 2024 – October 1, 2024 About fundraising

The world's largest scientific articles store. 70,000,000+ articles for free.

Fundraising September 15, 2024 – October 1, 2024

Z-Library is one of the largest online libraries in the world that contains over 17,000,000 books and 84,837,000 articles. We aim to make literature accessible to everyone. Today (September 15, 2024) we've started additional fundraising to project maintenance and development.

Also UNLIMITED downloads (for 31 days after the day of making donation) are available for ALL contributors who will donate during the fundraising period till October 1, 2024.

About fundraisingRead more

Make a donation

1

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

Franklin, Miriam, Gentles, Lucy, Matheson, Elizabeth, Bown, Nick, Cross, Paul, Ralte, Angela, Gilkes-Immeson, Connor, Bradbury, Alice, Zanjirband, Maryam, Lunec, John, Drew, Yvette, O'Donnell, Rachel,

Journal:

Cancer Medicine

Year:

2018

Language:

english

File:

PDF, 982 KB

english, 2018

2

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

Mukhopadhyay, Asima, Drew, Yvette, Matheson, Elizabeth, Salehan, Mo, Gentles, Lucy, Pachter, Jonathan A., Curtin, Nicola J.

Journal:

Biochemical Pharmacology

Year:

2018

Language:

english

File:

PDF, 1.48 MB

english, 2018

3

The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers

Yvette Drew, Hilary Calvert

Journal:

Annals of the New York Academy of Sciences

Year:

2008

Language:

english

File:

PDF, 243 KB

english, 2008

4

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

Yvette Drew, Ruth Plummer

Journal:

Drug Resistance Updates

Year:

2009

Language:

english

File:

PDF, 147 KB

english, 2009

5

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

Massard, Christophe, Margetts, Jane, Amellal, Nadia, Drew, Yvette, Bahleda, Ratislav, Stevens, Peter, Armand, Jean Pierre, Calvert, Hilary, Soria, Jean Charles, Coronado, Cinthya, Kahatt, Carmen, Alfa

Journal:

Investigational New Drugs

Year:

2013

Language:

english

File:

PDF, 171 KB

english, 2013

6

Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

Massard, Christophe, Margetts, Jane, Amellal, Nadia, Drew, Yvette, Bahleda, Ratislav, Stephens, Peter, Armand, Jean Pierre, Calvert, Hilary, Soria, Jean Charles, Coronado, Cinthya, Kahatt, Carmen, Alf

Journal:

Investigational New Drugs

Year:

2013

Language:

english

File:

PDF, 49 KB

english, 2013

7

The development of PARP inhibitors in ovarian cancer: from bench to bedside

Journal:

British Journal of Cancer

Year:

2015

Language:

english

File:

PDF, 753 KB

english, 2015

8

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Drew, Yvette, Ledermann, Jonathan, Hall, Geoff, Rea, Daniel, Glasspool, Ros, Highley, Martin, Jayson, Gordon, Sludden, Julieann, Murray, James, Jamieson, David, Halford, Sarah, Acton, Gary, Backholer,

Journal:

British Journal of Cancer

Year:

2016

Language:

english

File:

PDF, 526 KB

english, 2016

9

Homologous recombination deficiency and ovarian cancer

Ledermann, Jonathan A., Drew, Yvette, Kristeleit, Rebecca S.

Journal:

European Journal of Cancer

Year:

2016

Language:

english

File:

PDF, 1.09 MB

english, 2016

10

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer

Drew, Yvette, Plummer, Ruth

Journal:

Current Opinion in Obstetrics & Gynecology

Year:

2010

Language:

english

File:

PDF, 317 KB

english, 2010

11

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

Jamieson, David, Griffin, Melanie J., Sludden, Julieann, Drew, Yvette, Cresti, Nicola, Swales, Karen, Merriman, Mark, Allen, Rodger, Bevan, Paul, Buerkle, Markus, Mala, Carola, Coyle, Vicky, Rodgers,

Journal:

European Journal of Cancer

Year:

2016

Language:

english

File:

PDF, 722 KB

english, 2016

12

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Drew, Yvette, Ledermann, Jonathan, Hall, Geoff, Rea, Daniel, Glasspool, Ros, Highley, Martin, Jayson, Gordon, Sludden, Julieann, Murray, James, Jamieson, David, Halford, Sarah, Acton, Gary, Backholer,

Journal:

British Journal of Cancer

Year:

2016

Language:

english

File:

PDF, 103 KB

english, 2016

13

A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors

Kristeleit, Rebecca, Shapiro, Geoffrey I., Burris, Howard A., Oza, Amit M, LoRusso, Patricia M., Patel, Manish, Domchek, Susan M., Balmaña, Judith, Drew, Yvette, Chen, Lee-may, Safra, Tamar, Montes, A

Journal:

Clinical Cancer Research

Year:

2017

Language:

english

File:

PDF, 1.07 MB

english, 2017

14

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw-Tsai, Sarah, Xiao

Journal:

Clinical Pharmacology in Drug Development

Year:

2018

Language:

english

File:

PDF, 464 KB

english, 2018

15

Targeting the ATR-CHK1 Axis in Cancer Therapy

Rundle, Stuart, Bradbury, Alice, Drew, Yvette, Curtin, Nicola

Journal:

Year:

2017

Language:

english

File:

PDF, 2.96 MB

english, 2017

16

Array

Mariappan, Lavanya, Jiang, Xue Yan, Jackson, Josie, Drew, Yvette

Journal:

International Journal of Women's Health

Year:

2017

Language:

english

File:

PDF, 661 KB

english, 2017

17

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

Gentles, Lucy, Goranov, Bojidar, Matheson, Elizabeth, Herriott, Ashleigh, Kaufmann, Angelika, Hall, Sally, Mukhopadhyay, Asima, Drew, Yvette, Curtin, Nicola, O’Donnell, Rachel

Journal:

Year:

2019

File:

PDF, 1.70 MB

2019

18

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Curtin, Nicola J., Drew, Yvette, Sharma-Saha, Sweta

Journal:

Nature Reviews Clinical Oncology (formerly Nature Clinical Practice Oncology)

Year:

2019

Language:

english

File:

PDF, 530 KB

english, 2019

19

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.

Journal:

Year:

2019

Language:

english

File:

PDF, 559 KB

english, 2019

20

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Hong, David S., Concin, Nicole, Vergote, Ignace, de Bono, Johann S., Slomovitz, Brian M, Drew, Yvette, Arkenau, Hendrik-Tobias, Machiels, Jean-Pascal, Spicer, James, Jones, Robert, Forster, Martin, Co

Journal:

Clinical Cancer Research

Year:

2019

File:

PDF, 907 KB

2019

21

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Fordham, Sarah E., Blair, Helen J., Elstob, Claire J., Plummer, Ruth, Drew, Yvette, Curtin, Nicola J., Heidenreich, Olaf, Pal, Deepali, Jamieson, David, Park, Catherine, Pollard, John, Fields, Scott,

Journal:

Year:

2018

File:

PDF, 2.45 MB

2018

22

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA -mutated, high-grade ovarian cancer, and an update on safety

Kristeleit, Rebecca S, Oaknin, Ana, Ray-Coquard, Isabelle, Leary, Alexandra, BalmaÃ±a, Judith, Drew, Yvette, Oza, Amit M, Shapira-Frommer, Ronnie, Domchek, Susan M, Cameron, Terri, Maloney, Lara, Gobl

Journal:

International Journal of Gynecological Cancer

Year:

2019

File:

PDF, 373 KB

2019

23

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

Plummer, Ruth, Dua, Divyanshu, Cresti, Nicola, Drew, Yvette, Stephens, Peter, Foegh, Marie, Knudsen, Steen, Sachdev, Pallavi, Mistry, Bipin M., Dixit, Vaishali, McGonigle, Sharon, Hall, Nancy, Matijev

Journal:

British Journal of Cancer

Year:

2020

File:

PDF, 443 KB

2020

24

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting

Bradbury, Alice, OâDonnell, Rachel, Drew, Yvette, Curtin, Nicola J., Sharma Saha, Sweta

Journal:

Year:

2020

File:

PDF, 2.51 MB

2020

25

First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

Yap, Timothy A., Tan, David SP, Terbuch, Angelika, Caldwell, Reece, Guo, Christina, Goh, Boon Cher, Heong, Valerie, Haris, Noor R Md, Bashir, Saira, Drew, Yvette, Hong, David S., Meric-Bernstam, Funda

Journal:

Cancer Discovery

Year:

2020

File:

PDF, 5.87 MB

2020

26

Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer

Gentles, Lucy, Howarth, Rachel, Lee, Won Ji, Sharma-Saha, Sweta, Ralte, Angela, Curtin, Nicola, Drew, Yvette, O'Donnell, Rachel Louise

Journal:

Journal of Clinical Pathology

Year:

2020

File:

PDF, 3.12 MB

2020